Convection-Enhanced Delivery of a Synthetic Retinoid Am80, Loaded into Polymeric Micelles, Prolongs the Survival of Rats Bearing Intracranial Glioblastoma Xenografts

Yokosawa, Michiko; Sonoda, Yukihiko; Sugiyama, Shin; Saito, Ryuta; Yamashita, Yoshihisa; Nishihara, Masamichi; Satoh, Taku; Kumabe, Toshihiro; Yokoyama, Masayuki; Tominaga, Teiji

doi:10.1620/tjem.221.257

Cited by 22 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is a promising delivery method for large therapeutic agents such as monoclonal antibodies [36], antisense oligonucleotides [37], immunotoxins [38,39], or viral vectors [40,41]. It may prove beneficial in combination with radiotherapy for the treatment of brain tumors [42], and it can be combined with MRI to monitor drug delivery [43,44].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of vincristine administered via convection-enhanced delivery in a rodent brainstem tumor model documented by bioluminescence imaging

Rajaram

Mania-Farnell

et al. 2012

Childs Nerv Syst

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of vincristine administered via convection-enhanced delivery in a rodent brainstem tumor model documented by bioluminescence imaging

Rajaram

Mania-Farnell

et al. 2012

Childs Nerv Syst

View full text Add to dashboard Cite

show abstract

“…This is thought to be secondary to increased control over particle size. Various compounds have been loaded into micelles and administered via CED, including retinoic acid receptor agonists and doxorubicin [58,59]. These studies confirm adequate drug distribution and demonstrate therapeutic efficacy.…”

Section: • • Preclinical Studies: Systemic Deliverymentioning

confidence: 76%

Nanocarrier-based therapies for CNS tumors

Patel

2014

CNS Oncol.

View full text Add to dashboard Cite

Current chemotherapeutic strategies for tumors of the CNS are largely ineffective. This is due, in part, to the lack of robust drug delivery systems. The blood-brain barrier hinders the passage of systemically delivered therapeutics, and the brain extracellular matrix limits the distribution and longevity of locally delivered agents. Drug-loaded nanocarriers represent a promising strategy to overcome these barriers. Due to their small size and versatile design, nanocarriers can be finely tuned to address specific drug delivery challenges. Here, we review the major advances in development of nanocarrier-based therapeutics for tumors of the CNS, with an emphasis on polymeric nanoparticles.

show abstract

“…Reduced proliferation, invasion and migration of U87 cells, decreased number of colonies of these cells, increased number of apoptotic cells and reduced tumor volumes have been found upon treatment of cells with 6-OH-11-O-hydroxyfenantrene (IIF), an RXR agonist, and pioglitazone, a synthetic PPARγ agonist [ 425 ]. Systemic administration of TMZ combined with convection-enhanced delivery (direct intracranial drug infusion technique) of polymeric micellar Am80, a synthetic agonist with high affinity to nuclear RAR, provided longer survival of rats with GBM xenografts compared to controls [ 390 ].…”

Section: Targeting Retinoic Acid Signaling Pathway In Gbmmentioning

confidence: 99%

“…Summary of inhibitors of the CYP26A1 enzyme (RAMBAs) and RARs/RXRs agonists is made based on [ 383 ] and (accessed on 23 May 2022), respectively. RAR and RXR agonists and RAMBAs used for treatment of GBM cells in vitro or in vivo are presented in green letters, and RAR and RXR agonists and RAMBAs used in clinical trials for GBMs are presented in blue letters, while RAR and RXR agonists and RAMBAs not yet used in treatment of GBM are presented in black letters (based on results of previously reported publications included in the main text and results obtained by [ 385 , 386 , 387 , 388 , 389 , 390 ]).…”

Section: Figurementioning

confidence: 99%

Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma

Drakulić

Schwirtlich

Petrović

et al. 2022

Cells

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common and highly lethal type of brain tumor, with poor survival despite advances in understanding its complexity. After current standard therapeutic treatment, including tumor resection, radiotherapy and concomitant chemotherapy with temozolomide, the median overall survival of patients with this type of tumor is less than 15 months. Thus, there is an urgent need for new insights into GBM molecular characteristics and progress in targeted therapy in order to improve clinical outcomes. The literature data revealed that a number of different signaling pathways are dysregulated in GBM. In this review, we intended to summarize and discuss current literature data and therapeutic modalities focused on targeting dysregulated signaling pathways in GBM. A better understanding of opportunities for targeting signaling pathways that influences malignant behavior of GBM cells might open the way for the development of novel GBM-targeted therapies.

show abstract

Convection-Enhanced Delivery of a Synthetic Retinoid Am80, Loaded into Polymeric Micelles, Prolongs the Survival of Rats Bearing Intracranial Glioblastoma Xenografts

Cited by 22 publications

References 29 publications

Efficacy of vincristine administered via convection-enhanced delivery in a rodent brainstem tumor model documented by bioluminescence imaging

Efficacy of vincristine administered via convection-enhanced delivery in a rodent brainstem tumor model documented by bioluminescence imaging

Nanocarrier-based therapies for CNS tumors

Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma

Contact Info

Product

Resources

About